Fine Foods & Pharmaceuticals N.T.M Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Fine Foods & Pharmaceuticals N.T.M's earnings have been declining at an average annual rate of -41.6%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 10.6% per year. Fine Foods & Pharmaceuticals N.T.M's return on equity is 2%, and it has net margins of 1.1%.
Belangrijke informatie
-41.6%
Groei van de winst
-36.1%
Groei van de winst per aandeel
| Life Sciences Groei van de industrie | 26.8% |
| Inkomstengroei | 10.6% |
| Rendement op eigen vermogen | 2.0% |
| Nettomarge | 1.1% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Solid Earnings Reflect Fine Foods & Pharmaceuticals N.T.M's (BIT:FF) Strength As A Business
Sep 20
Is There An Opportunity With Fine Foods & Pharmaceuticals N.T.M. S.p.A.'s (BIT:FF) 40% Undervaluation?
Apr 28Estimating The Fair Value Of Fine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT:FF)
Mar 20Something To Consider Before Buying Fine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT:FF) For The 1.1% Dividend
Feb 22A Look At Fine Foods & Pharmaceuticals N.T.M's (BIT:FF) Share Price Returns
Feb 01What You Need To Know About Fine Foods & Pharmaceuticals N.T.M. S.p.A.'s (BIT:FF) Investor Composition
Jan 14We Wouldn't Rely On Fine Foods & Pharmaceuticals N.T.M's (BIT:FF) Statutory Earnings As A Guide
Dec 28Is Fine Foods & Pharmaceuticals N.T.M (BIT:FF) Using Too Much Debt?
Dec 08Opbrengsten en kosten
Hoe Fine Foods & Pharmaceuticals N.T.M geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 247 | 3 | 46 | 0 |
| 31 Mar 24 | 252 | -4 | 46 | 0 |
| 31 Dec 23 | 252 | -4 | 45 | 0 |
| 30 Sep 23 | 240 | 1 | 43 | 0 |
| 30 Jun 23 | 234 | -5 | 42 | 0 |
| 31 Mar 23 | 222 | -4 | 40 | 0 |
| 31 Dec 22 | 207 | -10 | 39 | 0 |
| 30 Sep 22 | 203 | -10 | 39 | 0 |
| 30 Jun 22 | 196 | -1 | 38 | 0 |
| 31 Mar 22 | 194 | -6 | 36 | 0 |
| 31 Dec 21 | 195 | -1 | 35 | 0 |
| 30 Sep 21 | 198 | -1 | 35 | 0 |
| 30 Jun 21 | 200 | 2 | 34 | 0 |
| 31 Mar 21 | 190 | 13 | 33 | 0 |
| 31 Dec 20 | 177 | 13 | 31 | 0 |
| 30 Sep 20 | 162 | 8 | 28 | 0 |
| 30 Jun 20 | 153 | -1 | 27 | 0 |
| 31 Mar 20 | 157 | -2 | 28 | 0 |
| 31 Dec 19 | 161 | -3 | 28 | 0 |
| 30 Sep 19 | 157 | 8 | 29 | 0 |
| 30 Jun 19 | 153 | 9 | 29 | 0 |
| 31 Mar 19 | 147 | 9 | 28 | 0 |
| 31 Dec 18 | 140 | 9 | 26 | 0 |
Kwaliteitswinsten: FF has high quality earnings.
Groeiende winstmarge: FF became profitable in the past.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: FF's earnings have declined by 41.6% per year over the past 5 years.
Versnelling van de groei: FF has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Winst versus industrie: FF has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (-0.7%).
Rendement op eigen vermogen
Hoge ROE: FF's Return on Equity (2%) is considered low.